SAN FRANCISCO — SEP-363856, a novel psychotropic agent with a non-D2 mechanism of action, showed statistically significant and clinically meaningful symptom improvement in patients with schizophrenia, according to data from a 4-week study presented at the APA annual meeting.

SEP-363856 also demonstrated robust activity across positive, negative, depressive and general psychopathology symptoms, the results showed.